M. Heywood

2.1k total citations · 1 hit paper
26 papers, 1.5k citations indexed

About

M. Heywood is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, M. Heywood has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Reproductive Medicine, 11 papers in Obstetrics and Gynecology and 8 papers in Surgery. Recurrent topics in M. Heywood's work include Ovarian cancer diagnosis and treatment (22 papers), Endometrial and Cervical Cancer Treatments (10 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). M. Heywood is often cited by papers focused on Ovarian cancer diagnosis and treatment (22 papers), Endometrial and Cervical Cancer Treatments (10 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). M. Heywood collaborates with scholars based in Canada, Australia and Austria. M. Heywood's co-authors include Robert Lotocki, Garry V. Krepart, Val Gebski, Ignace Vergote, Chris Brown, Uwe Wagner, Éric Pujade-Lauraine, Sandro Pignata, Annamaria Ferrero and P. Vasey and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Gynecologic Oncology.

In The Last Decade

M. Heywood

26 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →

Peers

M. Heywood

SURGE

ONCOL

PRM

Tom Ehlen Canada

T Maggino Italy

Alison H. Brand Australia

David M. Gershenson United States

Roberto Montera Italy

Corrado Terranova Italy

David Warshal United States

Ralph H.M. Hermans Netherlands

U. Ulrich Germany

Paolo Casadio Italy

Tom Ehlen Canada

M. Heywood

1.8k ×1.7

1.2k ×2.2

SURGE

904 ×1.7

448 ×1.0

ONCOL

186 ×1.3

PRM

Citations per year, relative to M. Heywood M. Heywood (= 1×) peers Tom Ehlen

Countries citing papers authored by M. Heywood

Since Specialization

Citations

This map shows the geographic impact of M. Heywood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Heywood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Heywood more than expected).

Fields of papers citing papers by M. Heywood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Heywood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Heywood. The network helps show where M. Heywood may publish in the future.

Co-authorship network of co-authors of M. Heywood

This figure shows the co-authorship network connecting the top 25 collaborators of M. Heywood. A scholar is included among the top collaborators of M. Heywood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Heywood. M. Heywood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Chee Khoon, Sarah J. Lord, Val Gebski, et al.. (2014). Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecologic Oncology. 136(1). 18–24. 40 indexed citations

You, Benoît, Olivier Colomban, M. Heywood, et al.. (2013). The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study). Gynecologic Oncology. 130(2). 289–294. 42 indexed citations

Brotto, Lori A., Mark Carey, Tom Ehlen, et al.. (2012). A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecologic Oncology. 125(2). 320–325. 191 indexed citations

Wagner, Uwe, Christian Marth, R. Largillier, et al.. (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British Journal of Cancer. 107(4). 588–591. 130 indexed citations

Mackay, Helen, et al.. (2011). Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21. Current Oncology. 18(2). 84–90. 16 indexed citations

Kwon, Janice S., Dianne Miller, Tom Ehlen, et al.. (2011). The significance of surgical staging in intermediate-risk endometrial cancer. Gynecologic Oncology. 122(1). 50–54. 11 indexed citations

Pujade-Lauraine, Éric, Uwe Wagner, Val Gebski, et al.. (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology. 28(20). 3323–3329. 410 indexed citations breakdown →

Pujade-Lauraine, Éric, Sven� Mahner, J. Kærn, et al.. (2009). A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). Journal of Clinical Oncology. 27(15_suppl). LBA5509–LBA5509. 44 indexed citations

Åvall‐Lundqvist, E., Pauline Wimberger, Laurence Gladieff, et al.. (2008). Pegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study. Journal of Clinical Oncology. 26(15_suppl). 5565–5565. 5 indexed citations

10.

Lotocki, Robert, et al.. (2005). Stage II endometrial carcinoma: Limiting post-operative radiotherapy to the vaginal vault in node-negative tumors. Gynecologic Oncology. 98(3). 434–438. 22 indexed citations

11.

Faught, Wylam, Tien Le, Michael Fung Kee Fung, et al.. (2003). Early Ovarian Cancer: What Is the Staging Impact of Retroperitoneal Node Sampling?. Journal of Obstetrics and Gynaecology Canada. 25(1). 18–21. 17 indexed citations

12.

Lotocki, Robert, et al.. (2003). High-risk surgical stage 1 endometrial cancer: outcomes with vault brachytherapy alone. Gynecologic Oncology. 89(2). 288–294. 28 indexed citations

13.

Le, Tien, et al.. (2002). The Benefits of Comprehensive Surgical Staging in the Management of Early-Stage Epithelial Ovarian Carcinoma. Gynecologic Oncology. 85(2). 351–355. 88 indexed citations

14.

Le, Tung B. K., Garry V. Krepart, Robert Lotocki, & M. Heywood. (1999). Clinically Apparent Early Stage Invasive Epithelial Ovarian Carcinoma: Should All Be Treated Similarly?. Gynecologic Oncology. 74(2). 252–254. 19 indexed citations

15.

Le, Trung, Garry V. Krepart, Robert Lotocki, & M. Heywood. (1997). Malignant Mixed Mesodermal Ovarian Tumor Treatment and Prognosis: A 20-Year Experience. Gynecologic Oncology. 65(2). 237–240. 39 indexed citations

16.

Le, Tung B. K., Garry V. Krepart, Robert Lotocki, & M. Heywood. (1997). Does Debulking Surgery Improve Survival in Biologically Aggressive Ovarian Carcinoma?. Gynecologic Oncology. 67(2). 208–214. 86 indexed citations

17.

Faught, Wylam, Garry V. Krepart, Robert Lotocki, & M. Heywood. (1994). Should Selective Paraaortic Lymphadenectomy Be Part of Surgical Staging for Endometrial Cancer?. Gynecologic Oncology. 55(1). 51–55. 41 indexed citations

18.

Semelka, Richard C., Patrick Lawrence, J. Patrick Shoenut, et al.. (1993). Primary ovarian cancer: Prospective comparison of contrast‐enhanced CT and pre‐and postcontrast, fat‐ suppressed MR imaging, with histologic correlation. Journal of Magnetic Resonance Imaging. 3(1). 99–106. 63 indexed citations

19.

Lotocki, Robert, et al.. (1992). Glassy cell carcinoma of the cervix: A bimodal treatment strategy. Gynecologic Oncology. 44(3). 254–259. 24 indexed citations

20.

Fung, Michael Fung Kee, et al.. (1991). Tubular Krukenberg tumor in pregnancy with virilization. Gynecologic Oncology. 41(1). 81–84. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact